Policy Background and Direction
South Korea's Ministry of Trade, Industry and Energy (MOTIE) is set to launch the Cell and Gene Therapy (CGT) Manufacturing Process Advancement R&D Program as part of its 2026 Second Bio-Health R&D Announcement. At the heart of this initiative is a policy push to resolve the manufacturing yield and quality-consistency issues that have long bottlenecked the CGT industry, using AI-driven process optimization.
CGT manufacturing—spanning cell culture, transduction, and purification—has historically suffered from significant batch-to-batch variability, driving up costs and increasing the risk of quality failures at the commercialization stage. The government's approach combines AI and big-data-based process monitoring, digital twins, and in-line Process Analytical Technology (PAT) to address these structural challenges.
Domestic biotech firms such as Helixmith have recently been selected for government R&D projects centered on manufacturing platform advancement, signaling a broader policy shift: manufacturing technology itself is increasingly viewed as a national competitiveness asset, not merely a downstream concern after drug candidate discovery.
Funding Scale and Project Structure
The program is designed as a roughly five-year, mid-to-long-term initiative, with total government funding expected to reach around KRW 30 billion. Early-stage funding (years 1-2) is expected to focus on securing core process platform technologies, while later stages (years 3-5) will concentrate on GMP-linked scale-up and validation.
Projects are structured around a lead research institution (a company or research institute) partnering with universities and government-funded research institutes as co-research institutions. Evaluators are expected to place particular weight on the division of roles between institutions holding core manufacturing process technology and companies with GMP validation capacity.
Eligibility and Application Process
Announcements and applications are managed through IRIS (the Integrated Research Support System). Companies preparing to apply should carefully review the program objectives, eligibility criteria, and evaluation indicators as soon as the announcement is posted, and assess the alignment between their current Technology Readiness Level (TRL) and the program's requirements.
When forming a consortium, it is critical to clearly define each participating institution's role and contribution rather than simply assembling a sufficient number of partners. Evaluators typically focus on three axes: (1) technological differentiation and innovation, (2) commercialization potential and market impact, and (3) the consortium's execution capacity and role fit—so applicants should ensure these three elements are consistently addressed throughout the proposal.
How KITIM Consulting Can Help
KITIM (Korea Institute of Technology Innovation Management) offers the following consulting services for companies preparing to apply to the CGT Manufacturing Process Advancement program:
Government R&D announcements typically have short application windows and detailed evaluation criteria, making unprepared applications highly likely to fail. If you are considering applying to the CGT Manufacturing Process Advancement R&D Program, contact KITIM's expert consulting team for systematic support—from proposal planning to consortium formation and application drafting.